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2STRUCTURED ABSTRACT
BACKGROUND: Cellular senescence is a terminal cell-cycle arrest that occurs in response to
activated oncogenes and DNA-damaging chemotherapy. Whether cancer cell senescence
at diagnosis might be predictive for treatment outcome is unknown.
METHODS: A senescence index (SI) was developed and used to retrospectively correlate the
treatment outcome of 30 UICC stage IV colorectal cancer (CRC) patients with their SI at
diagnosis.
RESULTS: 5-fluorouracil/leucovorin-treated CRC patients achieved a significantly longer
progression-free survival when presenting with SI-positive tumours prior to therapy (median
12.0 vs. 6.0 months; P = 0.044).
CONCLUSION: Cancer cell senescence predicts treatment outcome in metastasized CRC.
Prospective analyses of larger patient cohorts are needed.
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INTRODUCTION
In the past, many cancer studies sought to link quantitative assessments of tumour growth
properties, namely proliferation and apoptosis, to treatment outcome, but the majority of these
analyses produced negative results for various reasons. Although relevant as a prognosticator,
the value of utilizing the mitotic index to predict treatment outcome is very limited (see
(Brown & Attardi, 2005; Schmitt, 2003; Schmitt, 2007; Yerushalmi et al., 2010) for review
and references therein). A third cancer-related growth condition is oncogene-induced
senescence (OIS), a terminal cell-cycle arrest initiated by activated Ras-type oncogenes that
acts as a tumour-suppressive barrier in pre-malignant lesions in vivo (Braig et al., 2005;
Collado & Serrano, 2010; Michaloglou et al., 2005; Reimann et al., 2010). OIS is mediated
via an oncogene-evoked DNA damage response (DDR) (Bartkova et al., 2005; Bartkova et
al., 2006; Gorgoulis et al., 2005), thereby explaining why DNA-damaging chemotherapy
produces senescence as well (Chang et al., 1999; Schmitt et al., 2002). Therapy-induced
senescence (TIS) contributes to treatment outcome in pre-clinical models (Schmitt et al.,
2002), and is detectable in patient cancer biopsies after neoadjuvant chemotherapy (Roberson
et al., 2005; te Poele et al., 2002), but its long-term impact on clinical courses remains
3undetermined. We hypothesized that sporadically senescent cells present in untreated cancers
at diagnosis may indicate an increased susceptibility to TIS, and, thus, might be associated
with a superior clinical outcome. Since the gold-standard senescence assay, detection of the
senescence-associated β-galactosidase (SA-β-gal) activity (Dimri et al., 1995), cannot be
applied to formalin-fixed and paraffin-embedded (FFPE) clinical routine samples, we
developed a senescence index (SI) based on FFPE-suitable immunohistochemical surrogate
markers. We report here the first-time utilization of this SI in untreated human tumour
specimens at diagnosis as a predictor for outcome to cancer therapy.
MATERIALS AND METHODS
Patients and tumour material
Snap-frozen or formalin-fixed and paraffin-embedded (FFPE) samples of normal colon
mucosa, colon adenoma and colon carcinoma were collected, and informed patient consent
was obtained for the anonymous use of the material. FFPE tumour samples from previously
untreated 30 patients with UICC stage IV colorectal cancer (CRC) who all received a 5-
fluorouracil/leucovorin (5-FU/LV)-based first-line regimen were subjected to senescence
evaluation, reflecting the available archive material in our pathology department between the
years 1996 and 2003 that met these criteria. Tissue material from patients suspected or
diagnosed with a hereditary cancer syndrome or inflammatory bowel disease, or whose
chemotherapy was terminated for reasons other than disease progression was excluded from
this study. Clinical data sets were compiled in a retrospective and anonymous manner, and
included gender, age, tumour location, carcinoembryonic antigen (CEA) serum levels, TNM
classification, tumour grading and progression-free survival (PFS), defined as the time from
first diagnosis until diagnosis of progressive disease (i.e. local recurrence of the primary
lesion, or growth of metastases, or occurrence of new metastatic lesions).
Retroviral infection
IMR90 human fibroblasts (CCl-186 from American Type Culture Collection, Manassas, VA,
USA) were stably transduced with the pBabe-Puro-H-RasV12 retrovirus (provided by S.
Lowe) or an empty vector as a control, and selected in puromycin as described (Braig et al.,
2005; Serrano et al., 1997). Cell pellets were snap-frozen in liquid nitrogen or processed as
FFPE pellets comparable to patient tissue samples.
4Immunohistochemical analysis
Cryosections (12 µm) were acetone-fixed and exposed to an anti-Ki67 primary antibody
(M7240, Dako, Glostrup, Denmark, 1:250 dilution) for 30 min. Antibody binding was
visualized via a chromogenic substrate in a streptavidin/alkaline phosphatase-amplified
secondary antibody according to the manufacturer’s recommendations (K0689, K0698,
K0625, X3021, all from Dako).
FFPE sections  (7 µm) were subjected to heat-induced antigen retrieval prior to incubation
with primary antibodies for 30 minutes. Primary antibodies against Ki67 (as above),
heterochromatin protein 1γ (HP1γ; MAB3450, Chemicon/Millipore, Billerica, MA, USA,
1:250), phospho-activated ERK1/2 (p-ERK; #4376, Cell Signaling Technology [CST],
Danvers, MA, USA, 1:50), plasminogen activator inhibitor-1 (PAI-1 [i.e. Ncl-PAI-1];
Novocastra, Newcastle upon Tyne, UK, 1:20), or cleaved caspase 3/Asp175 (#9661, CST,
1:200) were used, followed by the appropriate secondary antibody plus a streptavidin/alkaline
phosphatase conjugate or streptavidin/peroxidase kit and suitable chromogenic substrates such
as DAB (3,3´-diaminodbenzidine) or Fast Red (K0690, K3468, K5005, all from Dako).
The formula and the cut-off values of the senescence index (SI) were generated based on
the expression (i.e. the percentage of positive cells by immunostaining) of the three markers
p-ERK, HP1γ and PAI-1 in low-proliferating areas (arbitrarily defined as < 12 Ki67-positive
in an area of 100 cells) in a learning set of five adenoma samples. For each of the three
markers, a factor was generated that reflects the reciprocal percentage of cells that stained
positive in such areas averaged over these five adenomas. This factor was used as a
coefficient to equalize the marker’s relative individual contribution to the SI. Moreover, a
linear correction value was added to set the discrimination threshold to 0. Values between –1
and +1 were considered “non-conclusive”. SI values of individual cancer samples were
obtained in low-proliferating areas as well. See Figure 2 for further information on SI-related
technical procedures.
Senescence-associated β-galactosidase activity
Senescence-associated β-galactosidase (SA-β-gal) activity was detected at pH 6.0 in cryo-
preserved cells or tissue sections as described (Braig et al., 2005; Dimri et al., 1995). Cases
were considered senescent if their mean percentage of SA-β-gal-positive cells was higher than
the mean percentage of Ki67-positive cells.
5Ras mutation analysis
Genomic DNA was extracted from macro-dissected tumour cell-enriched areas of FFPE tissue
sections using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). PCR amplification of
the first exon of the k-ras gene was performed according to van den Brandt and colleagues
(Brink et al., 2003). The resulting 179 bp PCR product was sequenced using the BigDye
Terminator v1.1 Cycle Sequencing kit on a 3130 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). Hotspot codon 12 or 13 mutations were detected by comparison with
the germ-line sequence.
Statistical analysis
Statistical analyses (SPSS software package, release 17.0, SPSS, Munich, Germany) of
Kaplan-Meier survival plots were based on the log-rank (Mantel-Cox) test; additional
statistical comparisons utilized the Wilcoxon-Mann-Whitney test (to probe equal distribution
of age, frequency of Ki67-reactive and cleaved caspase 3-positive cells, and serum CEA
levels in patient subgroups), the exact Fisher’s test (with respect to gender, tumour
localization, sites of distant metastasis [one vs. more than one], and Ras mutations), and the
chi-square test (regarding the pT and the pN status). P -values < 0.05 were considered
significant.
RESULTS
We analyzed 23 snap-frozen colorectal tissue samples of normal mucosa, adenomas, and
untreated invasive carcinomas by the SA-β-gal assay, complemented by immunostaining for
the proliferation marker Ki67, and confirmed the reportedly high frequency of senescent cells
in adenomas, leading to the classification of 8 out of 12 adenoma cases tested as senescent,
which is well in line with their macroscopic presentation as polyps of often stable size for
years (Figure 1A and B; see the flow diagram in Figure 2A for technical details) (Bartkova et
al., 2006). Importantly, as previously reported for a subset of lymphoma, lung and breast
cancer specimens at manifestation (Reimann et al., 2010; Roberson et al., 2005; te Poele et al.,
2002), we detected a significant fraction of senescent cells within neoplastic epithelial areas
of manifest colorectal carcinomas, possibly indicating a still available senescence program at
this full-blown cancer stage (Figure 1A and B).
6Since the enzymatic SA-β-gal assay cannot be applied to FFPE routine samples, or
substituted by a single marker, we tested protein expression levels of a panel of DDR
mediators, cell-cycle regulators, chromatin-related proteins and others (Bartkova et al., 2006;
Collado & Serrano, 2006) in a well-established OIS reference model system – sections of
either snap-frozen or FFPE pellets of Ras-senescent vs. proliferating fibroblasts – that allowed
us to compare SA-β-gal staining and potential immunohistochemical surrogate markers in the
same material side by side (Serrano et al., 1997). Using this fibroblast model system followed
by first a learning and then a validation set of adenoma samples, we generated a senescence
surrogate score (senescence index, SI) based on the expression of p-ERK, HP1γ, and PAI-1 –
all of them previously linked to OIS (Lin et al., 1998; Narita et al., 2003; Serrano et al.,
1997)– that recapitulated SA-β-gal reactivity and adenoma senescence (Figure 1C, and
Figure 2).
We obtained the SI in low-proliferating areas of 30 independent UICC stage IV colorectal
cancer (CRC) samples prior to any drug treatment, and assigned these cases, based on a cut-
off value, to a (partly) senescent vs. a non-senescent group. All patients in this retrospective
analysis received a 5-FU/LV-based first-line regimen. Patients with senescent areas in their
tumour biopsies experienced a significantly longer progression-free survival (PFS) with a
median PFS of 12.0 vs. 6.0 months when compared to the non-senescent group (Figure 1D).
Notably, both groups did not exhibit statistically significant differences with respect to
gender, age, pT and pN status as well as localization of the primary tumour (colon vs.
rectum), extent of distant metastasis (one vs. more than one site), or CEA serum levels at
diagnosis, and exhibited indistinguishable rates of proliferation (i.e. averaged sample-wide
Ki67 reactivity) and apoptosis (i.e. mean frequency of cleaved caspase 3-positive cells) (data
not shown). Interestingly, K-Ras codon 12/13 mutations were found at a higher frequency (P
= 0.035) in the senescent group (Figure 1D; insert), suggesting that Ras mutations, if
associated with a senescent phenotype, may not necessarily serve as a predictor of poor
outcome, as reported by several studies in the past (Andreyev et al., 2001; Andreyev et al.,
1998; Benhattar et al., 1993; Roth et al., 2010).
DISCUSSION
This is the first report linking cellular senescence at diagnosis to treatment outcome in cancer.
Whether sporadic senescent cells in manifest tumours represent a few remainders of the pre-
7malignant condition, or indicate retained senescence susceptibility throughout the tumour is
currently not clear. Our data favour the latter explanation, postulating that TIS produced in
response to DNA-damaging chemotherapy in senescence-capable tumour cells contributes to
the overall outcome to therapy. Notably, an inverse correlation between the expression level
of another senescence marker, macroH2A, and the risk of recurrence has recently been
reported for lung cancer patients (Sporn et al., 2009; Zhang et al., 2005). Additional studies
are certainly needed to clarify whether a greater extent of sporadic cancer cell senescence
indeed translates into a higher frequency of TIS-positive cells in situ when analyzed in re-
biopsies a few days after chemotherapy. Moreover, a preserved pro-senescent cancer
capability might be therapeutically exploitable by novel senescence-inducing strategies that
do no longer damage DNA. The role of senescent cells at diagnosis as a novel predictor of
treatment outcome should be further evaluated in larger prospective trials.
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Figure Legends
Figure 1 Stratification of stage IV CRC samples by a senescence index (SI) predicts PFS to
first-line 5-FU/LV therapy. (A) Proportions of senescent cases in cryo-preserved colorectal
tissue sections of the indicated groups (normal crypt mucosa [n = 5 (0 senescent)]; adenoma
[n = 12 (8 senescent)], invasive carcinoma [n = 6 (1 senescent)]). Note that 9/12 adenoma
and 2/6 carcinoma cases would score “senescent” if judged in low-proliferating areas only
(see D).  (B) Average frequency of senescent cells per group (as in A), measured as the
percentage of SA-β-gal-positive (blue) cells, and compared to the rate of Ki67-positive (red
nuclear staining) cells (top: error bars represent the standard deviation; bottom: matched
areas of representative photomicrographs – a non-senescent normal crypt mucosa, a
senescent adenoma, and a formally non-senescent carcinoma [but displaying numerous
senescent cells]). Notably, in normal colorectal mucosa, only cells of the most differentiated
luminal mucosa stain SA-β-gal-positive. (C ) FFPE sections of pelleted Ras-infected
senescent (sen.) human fibroblasts (SA-β-gal-positive and Ki67-negative frozen material as a
reference) exhibit much stronger immunoreactivity for p-ERK, HP1γ, and cytoplasmic PAI-1
when compared to non-senescent (non-sen.) mock-infected fibroblasts. (D) SI values, based
on the expression of these three markers, were obtained in 30 cases of stage IV CRC
specimens at diagnosis, and utilized to stratify PFS following 5-FU/LV first-line chemotherapy
(senescent [n = 12; blue line] vs. non-senescent [n = 17; red line]; one case scored “not
conclusive” [see Figure 2B]). Genomic sequencing in a subset of these 29 specimens
identified K-Ras codon 12 or 13 mutations in 5/6 senescent, but only 2/11 non-senescent
cases (insert). Note that a primary stratification by the K-Ras mutation status unveiled no
significant differences in PFS (P = 0.128).
Figure 2 Generation and validation of the senescence index (SI). (A) Technical flow diagram
of the generation and application of the senescence index (SI) in a Ras-transduced human
fibroblast cell line and in colorectal tissue specimens. (B) Formula and cut-off values of the
SI based on the expression p-ERK, HP1γ and PAI-1. Coefficients reflect the reciprocal
average percentage of cells that stained positive for the respective marker in the learning
adenomas to normalize the relative weight of the three markers. The correction value –19
was chosen to set the discrimination threshold at 0, with the range between –1 and +1
considered “non-conclusive”. (C) The majority of validation set adenomas is senescent when
analyzed by the SI. A set of 7 matched samples (frozen and FFPE material from the same
adenoma) underscores the high concordance between the SA-β-gal/Ki67- (see definition in
“Materials and Methods”) and the SI-based assignment.
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